PAZOPANIB HYDROCHLORIDE - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for pazopanib hydrochloride and what is the scope of freedom to operate?

Pazopanib hydrochloride is the generic ingredient in two branded drugs marketed by Apotex, Novugen, Sun Pharm, Teva Pharms Inc, and Novartis, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for pazopanib hydrochloride. Seven suppliers are listed for this compound.

Summary for PAZOPANIB HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	5
NDAs:	5
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	102
Clinical Trials:	285
Patent Applications:	1,112
What excipients (inactive ingredients) are in PAZOPANIB HYDROCHLORIDE?	PAZOPANIB HYDROCHLORIDE excipients list
DailyMed Link:	PAZOPANIB HYDROCHLORIDE at DailyMed

Recent Clinical Trials for PAZOPANIB HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Center Groningen	Phase 4
Alliance for Clinical Trials in Oncology	Phase 2/Phase 3
Shenzhen Chipscreen Biosciences Co.Ltd	Phase 2

See all PAZOPANIB HYDROCHLORIDE clinical trials

Pharmacology for PAZOPANIB HYDROCHLORIDE

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for PAZOPANIB HYDROCHLORIDE

L01EX	Other protein kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for PAZOPANIB HYDROCHLORIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Inc	PAZOPANIB HYDROCHLORIDE	pazopanib hydrochloride	TABLET;ORAL	217517-001	Oct 19, 2023	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Novugen	PAZOPANIB HYDROCHLORIDE	pazopanib hydrochloride	TABLET;ORAL	218231-001	Apr 23, 2024	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Novartis	VOTRIENT	pazopanib hydrochloride	TABLET;ORAL	022465-002	Oct 19, 2009		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for PAZOPANIB HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	VOTRIENT	pazopanib hydrochloride	TABLET;ORAL	022465-001	Oct 19, 2009	⤷ Sign Up	⤷ Sign Up
Novartis	VOTRIENT	pazopanib hydrochloride	TABLET;ORAL	022465-002	Oct 19, 2009	⤷ Sign Up	⤷ Sign Up
Novartis	VOTRIENT	pazopanib hydrochloride	TABLET;ORAL	022465-002	Oct 19, 2009	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.